Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Overview

Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it with the individual drugs

Full Title of Study: “Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2011

Interventions

  • Drug: Nifedipine-candesartan FDC (BAY 98-7106)
    • Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
  • Drug: Nifedipine GITS (Adalat LA, BAYA1040)
    • Single oral dose of 1 tablet of nifedipine GITS 60 mg
  • Drug: Candesartan (Atacand)
    • Single oral dose of 32 mg (2 x 16 mg tablet) candesartan

Arms, Groups and Cohorts

  • Experimental: Nifedipine-candesartan FDC
    • Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
  • Active Comparator: Nifedipine and candesartan
    • Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
  • Active Comparator: Nifedipine
    • Each subject received one dose of nifedipine GITS 60 mg orally.
  • Active Comparator: Candesartan
    • Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.

Clinical Trial Outcome Measures

Primary Measures

  • Cmax
    • Time Frame: Within 48 hours after each treatment
    • Maximum drug concentration in plasma after dose administration for nifedipine and candesartan
  • AUC(0-tn)
    • Time Frame: Within 48 hours after each treatment
    • AUC from time 0 to the last data point for nifedipine and candesartan

Secondary Measures

  • AUC
    • Time Frame: Within 48 hours after each treatment
    • Area under the plasma concentration vs time curve from zero to infinity after single (first) dose for nifedipine and candesartan
  • Cmax,norm
    • Time Frame: Within 48 hours after each treatment
    • Maximum drug concentration in plasma after dose administration divided by dose (mg) per kg body weight for nifedipine and candesartan
  • AUCnorm
    • Time Frame: Within 48 hours after each treatment
    • Area under the curve divided by dose per kg body weight for nifedipine and candesartan
  • AUC(0-48)
    • Time Frame: Within 48 hours after each treatment
    • AUC from time 0 to time 48 h for nifedipine and candesartan
  • tmax
    • Time Frame: Within 48 hours after each treatment
    • Time to reach maximum drug concentration in plasma after single (first) dose for nifedipine and candesartan
    • Time Frame: Within 48 hours after each treatment
    • Half-life associated with the terminal slope for nifedipine and candesartan
  • MRT
    • Time Frame: Within 48 hours after each treatment
    • Mean residence time for nifedipine and candesartan
  • CL/f
    • Time Frame: Within 48 hours after each treatment
    • Total body clearance of drug from plasma calculated after oral administration (apparent oral clearance) for nifedipine and candesartan
  • Number of participants with adverse events
    • Time Frame: Approximately 3.5 months

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male subject – Age: 18 to 45 years (inclusive) at the first screening / examination visit – Ethnicity: Caucasian – Body mass index (BMI): >/=18 and </=29,9 kg/m² Exclusion Criteria:

  • Systolic blood pressure below 120 or above 145 mmHg – Diastolic blood pressure above 95 mmHg – Heart rate below 45 or above 95 beats / min – Clinically relevant findings in the physical examination – Suspicion of drug or alcohol abuse – Regular daily consumption of more than 1 L of xanthin-containing beverages – Intake of foods or beverages containing grapefruit within 4 weeks before the pre-study examination

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Citations Reporting on Results

Brendel E, Weimann B, Dietrich H, Froede C, Thomas D. Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions. Int J Clin Pharmacol Ther. 2013 Sep;51(9):753-62. doi: 10.5414/CP201879.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.